Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Omeros Corp (NASDAQ:OMER)

Thursday’s trading has closed, but OMER is being traded in the after-hours session. After-Hours quote »
12.60
Delayed Data
As of 3:59pm ET
 -0.87 / -6.46%
Today’s Change
11.18
Today|||52-Week Range
30.23
-49.15%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$510.3M

Company Description

Omeros Corp. is a clinical stage biopharmaceutical company, which engages in the discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Its products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. The company also has a deep and diverse pipeline of preclinical programs as well as a platform capable of unlocking new drug targets. Omeros was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Contact Information

Omeros Corp.
201 Elliott Avenue West
Seattle Washington 98119
P:(206) 676-5000
Investor Relations:
(206) 676-5036

Employees

Shareholders

Individual stakeholders7.69%
Other institutional34.78%
Mutual fund holders27.46%

Top Executives

Gregory A. DemopulosChairman, President & Chief Executive Officer
David R. TollSenior Director-Finance
Michael A. JacobsenChief Financial Officer, Treasurer, CAO & VP
George A. GaitanarisChief Scientific Officer & Vice President
J. Steven WhitakerChief Medical Officer & VP-Clinical Development